A solution for dyspareunia in breast cancer survivors

a randomized controlled study

Martha Goetsch, Jeong Y. Lim, Aaron Caughey

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

INTRODUCTION: Research has focused on vaginal atrophy as the cause of dyspareunia in postmenopausal women. This study explored whether penetrative pain was prevented after hypoestrogenic patients applied analgesic liquid to the vulvar vestibule.

METHODS: In a randomized controlled, double-blind trial, estrogen-deficient breast cancer survivors with severe penetrative dyspareunia applied either saline or 4% aqueous lidocaine to the vulvar vestibule for 3 minutes before vaginal penetration. After a 1-month blinded trial using diary documentation of twice-weekly tampon insertion or intercourse, all patients received lidocaine in an open-label trial for 2 months. The primary outcome was penetration pain (0-10 numeric rating scale). Secondary outcomes were sexual distress (Female Sexual Distress Scale, abnormal greater than 11) and resumption of intercourse. Comparisons were made with the Wilcoxon rank sum and Wilcoxon signed rank test, with significance set at P

RESULTS: Forty-six patients, screened to exclude pelvic muscle and organ pain, uniformly had severe vulvovaginal atrophy, dyspareunia (median pain 8/10, interquartile range 7-9), and elevated sexual distress scores (median 30.5, interquartile 23-37). Users of lidocaine had less intercourse pain in the blinded phase (median score 1.0 compared with saline 5.3, P=.015). After open-label lidocaine use, 37 of 41 (90%) reported comfortable penetration. Sexual distress had decreased (median 14, interquartile range 3-20, P

CONCLUSION: Breast cancer survivors with severe menopausal dyspareunia associated with atrophy can have comfortable intercourse after applying topical liquid lidocaine to the vulvar vestibule before penetration.

Original languageEnglish (US)
Pages (from-to)1S
JournalObstetrics and Gynecology
Volume123
DOIs
StatePublished - May 1 2014

Fingerprint

Dyspareunia
Lidocaine
Survivors
Breast Neoplasms
Atrophy
Pain
Pelvic Pain
Myalgia
Nonparametric Statistics
Documentation
Analgesics
Estrogens
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A solution for dyspareunia in breast cancer survivors : a randomized controlled study. / Goetsch, Martha; Lim, Jeong Y.; Caughey, Aaron.

In: Obstetrics and Gynecology, Vol. 123, 01.05.2014, p. 1S.

Research output: Contribution to journalArticle

@article{e87699c2021b4acbbda7e2f29908ef29,
title = "A solution for dyspareunia in breast cancer survivors: a randomized controlled study",
abstract = "INTRODUCTION: Research has focused on vaginal atrophy as the cause of dyspareunia in postmenopausal women. This study explored whether penetrative pain was prevented after hypoestrogenic patients applied analgesic liquid to the vulvar vestibule.METHODS: In a randomized controlled, double-blind trial, estrogen-deficient breast cancer survivors with severe penetrative dyspareunia applied either saline or 4{\%} aqueous lidocaine to the vulvar vestibule for 3 minutes before vaginal penetration. After a 1-month blinded trial using diary documentation of twice-weekly tampon insertion or intercourse, all patients received lidocaine in an open-label trial for 2 months. The primary outcome was penetration pain (0-10 numeric rating scale). Secondary outcomes were sexual distress (Female Sexual Distress Scale, abnormal greater than 11) and resumption of intercourse. Comparisons were made with the Wilcoxon rank sum and Wilcoxon signed rank test, with significance set at PRESULTS: Forty-six patients, screened to exclude pelvic muscle and organ pain, uniformly had severe vulvovaginal atrophy, dyspareunia (median pain 8/10, interquartile range 7-9), and elevated sexual distress scores (median 30.5, interquartile 23-37). Users of lidocaine had less intercourse pain in the blinded phase (median score 1.0 compared with saline 5.3, P=.015). After open-label lidocaine use, 37 of 41 (90{\%}) reported comfortable penetration. Sexual distress had decreased (median 14, interquartile range 3-20, PCONCLUSION: Breast cancer survivors with severe menopausal dyspareunia associated with atrophy can have comfortable intercourse after applying topical liquid lidocaine to the vulvar vestibule before penetration.",
author = "Martha Goetsch and Lim, {Jeong Y.} and Aaron Caughey",
year = "2014",
month = "5",
day = "1",
doi = "10.1097/AOG.0000000000000203",
language = "English (US)",
volume = "123",
pages = "1S",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - A solution for dyspareunia in breast cancer survivors

T2 - a randomized controlled study

AU - Goetsch, Martha

AU - Lim, Jeong Y.

AU - Caughey, Aaron

PY - 2014/5/1

Y1 - 2014/5/1

N2 - INTRODUCTION: Research has focused on vaginal atrophy as the cause of dyspareunia in postmenopausal women. This study explored whether penetrative pain was prevented after hypoestrogenic patients applied analgesic liquid to the vulvar vestibule.METHODS: In a randomized controlled, double-blind trial, estrogen-deficient breast cancer survivors with severe penetrative dyspareunia applied either saline or 4% aqueous lidocaine to the vulvar vestibule for 3 minutes before vaginal penetration. After a 1-month blinded trial using diary documentation of twice-weekly tampon insertion or intercourse, all patients received lidocaine in an open-label trial for 2 months. The primary outcome was penetration pain (0-10 numeric rating scale). Secondary outcomes were sexual distress (Female Sexual Distress Scale, abnormal greater than 11) and resumption of intercourse. Comparisons were made with the Wilcoxon rank sum and Wilcoxon signed rank test, with significance set at PRESULTS: Forty-six patients, screened to exclude pelvic muscle and organ pain, uniformly had severe vulvovaginal atrophy, dyspareunia (median pain 8/10, interquartile range 7-9), and elevated sexual distress scores (median 30.5, interquartile 23-37). Users of lidocaine had less intercourse pain in the blinded phase (median score 1.0 compared with saline 5.3, P=.015). After open-label lidocaine use, 37 of 41 (90%) reported comfortable penetration. Sexual distress had decreased (median 14, interquartile range 3-20, PCONCLUSION: Breast cancer survivors with severe menopausal dyspareunia associated with atrophy can have comfortable intercourse after applying topical liquid lidocaine to the vulvar vestibule before penetration.

AB - INTRODUCTION: Research has focused on vaginal atrophy as the cause of dyspareunia in postmenopausal women. This study explored whether penetrative pain was prevented after hypoestrogenic patients applied analgesic liquid to the vulvar vestibule.METHODS: In a randomized controlled, double-blind trial, estrogen-deficient breast cancer survivors with severe penetrative dyspareunia applied either saline or 4% aqueous lidocaine to the vulvar vestibule for 3 minutes before vaginal penetration. After a 1-month blinded trial using diary documentation of twice-weekly tampon insertion or intercourse, all patients received lidocaine in an open-label trial for 2 months. The primary outcome was penetration pain (0-10 numeric rating scale). Secondary outcomes were sexual distress (Female Sexual Distress Scale, abnormal greater than 11) and resumption of intercourse. Comparisons were made with the Wilcoxon rank sum and Wilcoxon signed rank test, with significance set at PRESULTS: Forty-six patients, screened to exclude pelvic muscle and organ pain, uniformly had severe vulvovaginal atrophy, dyspareunia (median pain 8/10, interquartile range 7-9), and elevated sexual distress scores (median 30.5, interquartile 23-37). Users of lidocaine had less intercourse pain in the blinded phase (median score 1.0 compared with saline 5.3, P=.015). After open-label lidocaine use, 37 of 41 (90%) reported comfortable penetration. Sexual distress had decreased (median 14, interquartile range 3-20, PCONCLUSION: Breast cancer survivors with severe menopausal dyspareunia associated with atrophy can have comfortable intercourse after applying topical liquid lidocaine to the vulvar vestibule before penetration.

UR - http://www.scopus.com/inward/record.url?scp=84925283070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925283070&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000000203

DO - 10.1097/AOG.0000000000000203

M3 - Article

VL - 123

SP - 1S

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

ER -